NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

急性呼吸窘迫症候群(ARDS):市場分析,流行病學,市場預測(2030)

Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast -2030

出版商 DelveInsight Business Research LLP 商品編碼 971970
出版日期 按訂單生產 內容資訊 英文 314 Pages
商品交期: 2-10個工作天內
價格
急性呼吸窘迫症候群(ARDS):市場分析,流行病學,市場預測(2030) Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast -2030
出版日期: 按訂單生產內容資訊: 英文 314 Pages
簡介

在本報告中,全球7個主要國家(美國),5個主要歐洲國家(歐盟5國:法國,德國,意大利,西班牙,英國),日本-的急性呼吸窘迫症候群(ARDS)的流行病學趨勢和未來趨勢分析市場前景,概述疾病和基本市場結構,當前治療方法和未滿足的需求,流行趨勢展望,市場/研究治療方法的概況,全球/國家市場規模(我們將為您提供過去3年和以後11年的信息,主要的市場推廣和限制因素。

目錄

第1章主要討論

第2章執行摘要

第3章:急性呼吸窘迫症候群(ARDS):市場概況

  • 整體市場佔有率結構(2017)
  • 總體市場佔有率結構(2030年)

第4章:急性呼吸窘迫症候群(ARDS):疾病的背景和概述

  • 簡介
  • 原因和危險因素
    • 急性呼吸窘迫症候群(ARDS)的危險因素
  • 急性呼吸窘迫症候群(ARDS)的病理生理學
    • ARDS炎症過程
    • 染病的前兆
    • 心內膜損害
    • ARDS中炎症和肺損傷的特定介質
    • ARDS的肺生理變化
    • 遺傳學
  • 急性呼吸窘迫症候群(ARDS)的階段
  • 人工呼吸器(VILI)對肺的傷害
  • VILI的主要決定因素
    • 人工呼吸器一側的VILI的決定因素
    • VILI患者端決定因素
  • 如何診斷急性呼吸窘迫綜合徵(ARDS)
    • ARDS影像技術
    • ARDS圖像發現
    • 鑑別診斷

第5章病例報告

  • 帶ARDS的COVID-19:醫師的觀點
  • 高流量氧氣療法治療多發性ARDS合併支原體肺炎
  • ARDS嚴重體溫過低:病例報告

第6章流行病學和患者人群

  • 分析要點
  • 分析方法

第7章對7個主要國家的流行病學分析

  • 急性呼吸窘迫症候群(ARDS)病例數:總數
  • 急性呼吸窘迫症候群(ARDS)病例數:按嚴重程度

第8章美國的流行病學趨勢

  • 假設和理由
  • 急性呼吸窘迫症候群(ARDS)病例數:總數
  • 急性呼吸窘迫症候群(ARDS)病例數:按嚴重程度
  • 急性呼吸窘迫症候群(ARDS)病例數:按危險因素

第9章,五個歐洲國家的流行病學趨勢

  • 德國流行病學趨勢
  • 法國的流行病學趨勢
  • 意大利的流行病學趨勢
  • 西班牙的流行病學趨勢
  • 英國流行病學趨勢

第10章日本的流行病學趨勢

第11章治療算法,當前治療方法和醫學實踐

  • 急性呼吸窘迫症候群(ARDS)的治療和支持
  • ALI/ARDS治療:與COVID-19的關係

第12章ARDS指南草案

第13章未滿足的需求

第14章ARDS的非適應症治療

  • 神經肌肉阻滯劑(NMBA)
    • 概述
    • 作用機理
    • 利與弊
    • 臨床試驗趨勢
  • 可吸入的血管擴張劑
    • 可吸入的肺血管擴張劑
  • 皮質類固醇

第15章新療法

  • 主要競爭
    • ARDS/ALI正在開發的產品列表
  • Traumakine:Faron Pharmaceuticals
    • 產品說明
    • 其他發展活動
    • 臨床發展
    • 臨床試驗信息
    • 安全性和有效性
    • 產品簡介
  • Bio-11006:BioMarck Pharmaceuticals
  • MultiStem:Athersys
  • Solnatide (AP301):APEPTICO Forschung und Entwicklung GmbH
  • Ultomiris (ravulizumab-cwvz):Alexion Pharma
  • Soliris (eculizumab):Alexion Pharma

第16章臨床階段未知的產品

  • 烏裡司他汀:Techpool生物製藥

第17章與ARDS相關的COVID-19:新藥

  • L-citrulline: Asklepion Pharmaceuticals
  • Cholecalciferol: Mylan Laboratories
  • Ruxolitinib: Incyte Corporation/Novartis
  • BDB-001: Staidson (Beijing) Biopharmaceuticals
  • RLF-100 (aviptadil): NeuroRx/Relief Therapeutics
  • Zavegepant/Vazegepant: Biohaven Pharmaceutical
  • Metablok (LSALT peptide): Arch Biopartners
  • Lenzilumab: Humanigen
  • Actemra/RoActemra (Tocilizumab): Roche Pharma AG
  • DSTAT (Dociparastat sodium): Chimerix
  • Pemziviptadil (PB1046): PhaseBio Pharmaceuticals
  • ExoFlo (DB-001): Direct Biologics
  • Veru-111: Veru
  • Tradipitant: Vanda Pharmaceuticals
  • Brexanolone: Sage Therapeutics
  • Mavrilimumab: Kiniksa Pharmaceuticals
  • Human immunoglobulin: Laboratoire francais de Fractionnement et de Biotechnologies (LFB)
  • Remestemcel-L: Mesoblast Limited
  • PLX-PAD: Pluristem Therapeutics
  • CERC-002: Cerecor
  • TD-0903: Theravance Biopharma
  • ILT101: ILTOO Pharma

第18章停產的產品

  • APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline
  • GSK2862277: GlaxoSmithKline
  • Remodulin (Treprostinil Inhalation Solution): United Therapeutics

第19章:急性呼吸窘迫綜合徵(ARDS):7個主要國家的市場分析

  • 主要分析結果
  • ARDS市場規模:7個主要國家
  • ARDS市場規模:按治療藥物劃分的7個主要國家

第20章屬性分析

第21章主要新療法:市場預測的前提

第22章美國:市場前景

  • 美國市場規模
    • ARDS市場規模:總體
    • ARDS市場規模:按治療藥物劃分

第23章:五個歐洲國家:市場前景

  • 德國市場規模
    • ARDS市場規模:總體
    • ARDS市場規模:按治療藥物劃分
  • 法國市場規模
  • 意大利市場規模
  • 西班牙市場規模
  • 英國市場規模

第24章日本:市場前景

  • 日本市場規模
    • ARDS市場規模:總體
    • ARDS市場規模:按治療藥物劃分

第25章訪問和贖回

第26章市場促進因素

第27章市場抑制因素

第28章SWOT分析

第29章附錄

第30章Delve Insight Services

第31章免責聲明

第32章關於Delve Insight

目錄
Product Code: DIMI0011

DelveInsight's 'Acute Respiratory Distress Syndrome (ARDS)-Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.

The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acute Respiratory Distress Syndrome (ARDS) Disease Understanding and Treatment Algorithm

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions. The few symptoms of ARDS are shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risks factors that may escalate the risk for ARDS; this involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

A novel strain of coronavirus emerged in December 2019, which was termed as COVID-19 by the World Health Organization (WHO). Coronaviruses belong to a family of viruses that range from the common cold to MERS coronavirus, which is Middle East Respiratory Syndrome and Severe acute respiratory syndrome (SARS) coronavirus. The clinical data of COVID-19 severely infected patients suggest that radiologic evidence of lung edema- a manifestation of ALI and may progress to hypoxemia and potentially ARDS-is common. The occurrence and severity of ALI are a major determining factor of the prognosis of patients with COVID-19 infection. About 30% of patients with COVID-19 infection in the ICU developed severe lung edema, dyspnea, hypoxemia, or even ARDS. COVID-19 patients diagnosed with ARDS have a poor prognosis and high mortality.

Acute Respiratory Distress Syndrome (ARDS) Diagnosis

The diagnosis of Acute Respiratory Distress Syndrome (ARDS) is based on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests.

ARDS is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes as hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.

Acute Respiratory Distress Syndrome (ARDS) Treatment

The Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, was described as a form of respiratory failure that closely resembled respiratory distress syndrome in infants. This can be caused by a variety of pulmonary (such as pneumonia, aspiration) or non-pulmonary (like sepsis, pancreatitis, and trauma) abuses, leading to the development of non-hydrostatic pulmonary edema. The treatment of ARDS involves general supportive measures, ventilator strategies, and appropriate treatment of the underlying condition. Besides general supportive measures, pharmacological interventions are commonly considered throughout ARDS. Although research involving the investigation of drug candidates is being carried out for over a decade, only a few pharmacological therapies have emerged for ARDS.

Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS. Other treatment options, which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.

It covers the details of conventional and current medical therapies available in the Acute Respiratory Distress Syndrome (ARDS) market for the treatment of the various types of Acute Respiratory Distress Syndrome (ARDS). It also provides the treatment guidelines and algorithms of the United States and Europe. The DelveInsight's Acute Respiratory Distress Syndrome (ARDS) market report gives a thorough understanding of Acute Respiratory Distress Syndrome (ARDS) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Acute Respiratory Distress Syndrome (ARDS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of ARDS, Severity-specific Incidence of ARDS, and Incidence of ARDS by Risk Factors scenario of Acute Respiratory Distress Syndrome (ARDS) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpses of the Acute Respiratory Distress Syndrome (ARDS) epidemiology in the 7MM.

  • In the 7MM, the total incident population of ARDS is estimated to be 799,872, in 2017.
  • Generally, the highest number of incident cases were assessed for ARDS due to Pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS.
  • Due to occurrence of COVID-19, there is a sudden increase in the cases of ARDS in the US, from 495,655 in 2017, to 550,371 in 2020.

Country Wise-Acute Respiratory Distress Syndrome (ARDS) Epidemiology

The epidemiology segment also provides the Acute Respiratory Distress Syndrome (ARDS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acute Respiratory Distress Syndrome (ARDS) Drug Chapters

The drug chapter segment of the Acute Respiratory Distress Syndrome (ARDS) report encloses the detailed analysis of Acute Respiratory Distress Syndrome (ARDS) marketed drugs and mid- and late-stage pipeline drugs. It also helps to understand the Acute Respiratory Distress Syndrome (ARDS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Acute Respiratory Distress Syndrome (ARDS) Emerging Drugs

Traumakine: Faron Pharmaceuticals

Interferon-beta-1a-also known as Traumakine; FP-1201-lyo; MR11A8; FP-1201; Recombinant Human IFN Beta-1a-is under development by Faron Pharmaceuticals as its lead drug candidate. It is a lyophilized powder form of recombinant human IFN beta-1a reconstituted in water for injection. It is administered intravenously, and targets the Interferon-beta receptor 1, activating its action. In January 2018, Faron Pharmaceuticals received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine, for the treatment of ARDS. The drug is in phase III (CALIBER Global Study) clinical developmental trial for the patients with ARDS.

Products detail in the report:

BIO-11006: BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is developing its lead compound BIO-11006 under the Phase II stage of development for the treatment of Adult Respiratory Distress Syndrome (ARDS). Biomarck's BIO-11006 is a novel, highly soluble, patented, 10 amino acid peptides. It acts as a MARCKS (Myristoylated alanine-rich C kinase substrate) protein inhibitor and is being developed to specifically target the MARCKS protein to inhibit cancer cell division and movement. Furthermore, it is a water-soluble, stable aerosolized anti-MARCKS peptide inhalation solution that involves aerosolized delivery of either the active drug or placebo by the "Aeroneb Pro nebulizer."

Products detail in the report:

MultiStem: Athersys

MultiStem-also known as AMI MultiStem; HLCM 051 and PF-05285401-is a patented regenerative product which can promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage and restore immune system balance. MultiStem is under development by Athersys and is currently in the Phase II stage for the treatment of Acute Respiratory Distress Syndrome. Currently, the US FDA granted Fast Track designation to Athersys for its clinical program evaluating MultiStem cell therapy for the treatment of ARDS.

Products detail in the report:

Solnatide: Apeptico Forschung und Entwicklung GmbH

Solnatide (AP301; synonym to TNF-derived TIP-peptide) under development by Apeptico Forschung und Entwicklung GmbH is a synthetic molecule whose structure bases on the lectin-like domain of the Human Tumor Necrosis Factor α. The AP301 peptide is water-soluble and can be administered into the lung by oral inhalation. The drug is conducting phase II clinical developmental trial in patients with ARDS.

Apart from these, Lenzilumab, tocilizumab (TCZ), aviptadil, ruxolitinib, tradipitant, and remestemcel-L, are the other pipeline therapies, which are expected to enter the market in the forecasted period that will be targeting the COVID-19 associated ARDS cases.

Lenzilumab: Humanigen, Inc.

Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate that is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial.

Products detail in the report:

Actemra/RoActemra (Tocilizumab): Roche Pharma AG

Actemra/RoActemra (Tocilizumab) is another investigational molecule that is in phase III stage of development for SARS-CoV-2 infection and evidence of systemic inflammation. From some studies, it has been observed that Tocilizumab can be a suitable and effective therapy for severe cases of COVID-19 associated with acute respiratory distress syndrome.

List to be continued in the report:

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

Despite recent advances in critical care, the mortality due to ARDS varies from 35% to 45% in various studies. The mortality has been reported to be associated with organ failure, sepsis, age, and associated comorbid illness. The treatment of ARDS involves general supportive measures, ventilator strategies, and appropriate treatment of the underlying condition. Besides general supportive measures, pharmacological interventions are commonly considered throughout ARDS. Although research involving the investigation of drug candidates is being carried out for over a decade, only a few pharmacological therapies have emerged for ARDS. In the off-label treatment options, STATIN therapy, NMBAs, and glucocorticosteroids are recommended because there is no approved therapy for this indication yet.

The Acute Respiratory Distress Syndrome (ARDS) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute Respiratory Distress Syndrome (ARDS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Acute Respiratory Distress Syndrome (ARDS) market trend of each late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Acute Respiratory Distress Syndrome (ARDS) 7MM market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Acute Respiratory Distress Syndrome (ARDS) 7MM market.

  • According to DelveInsight estimates, the United States accounts for the largest market size of Acute Respiratory Distress Syndrome (ARDS), in comparison to Japan and EU5 (Germany, Italy, France, UK and Spain).
  • The market size of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets was 917.81 Million in 2017.
  • Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of ARDS and awareness of the disease.

The United States Market Outlook

This section provides the total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Acute Respiratory Distress Syndrome (ARDS) market size and market size by therapies in Japan are provided.

Acute Respiratory Distress Syndrome (ARDS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome (ARDS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Respiratory Distress Syndrome (ARDS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Respiratory Distress Syndrome (ARDS) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Acute Respiratory Distress Syndrome (ARDS) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Acute Respiratory Distress Syndrome (ARDS) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Acute Respiratory Distress Syndrome (ARDS) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute Respiratory Distress Syndrome (ARDS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Acute Respiratory Distress Syndrome (ARDS) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.

Report Highlights:

  • Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is anticipated to rise in the forecasted period (2017-2030).
  • The market for ARDS in the 7MM is projected to rise during the study period (2017-2030).
  • Dynamic research and developmental activity with 60+ companies in the pipeline at different stages.
  • In the coming years, Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Acute Respiratory Distress Syndrome (ARDS). Launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome (ARDS) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acute Respiratory Distress Syndrome (ARDS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis
  • Acute Respiratory Distress Syndrome (ARDS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Respiratory Distress Syndrome (ARDS) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Acute Respiratory Distress Syndrome (ARDS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acute Respiratory Distress Syndrome (ARDS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Acute Respiratory Distress Syndrome (ARDS) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Acute Respiratory Distress Syndrome (ARDS) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Acute Respiratory Distress Syndrome (ARDS) market size during the forecast period (2020-2030)?
  • At what CAGR, the Acute Respiratory Distress Syndrome (ARDS) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Acute Respiratory Distress Syndrome (ARDS) market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Acute Respiratory Distress Syndrome (ARDS) market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Acute Respiratory Distress Syndrome (ARDS)?
  • What is the historical Acute Respiratory Distress Syndrome (ARDS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) at the 7MM level?
  • What will be the growth opportunities across the 7MM for the patient population pertaining to ARDS?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Acute Respiratory Distress Syndrome (ARDS) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Acute Respiratory Distress Syndrome (ARDS) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Acute Respiratory Distress Syndrome (ARDS) in the US and Europe?
  • What are the Acute Respiratory Distress Syndrome (ARDS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
  • How many therapies are developed by each company for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
  • How many emerging therapies are in the mid-stage and late-stage of development for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Respiratory Distress Syndrome (ARDS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Respiratory Distress Syndrome (ARDS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute Respiratory Distress Syndrome (ARDS)?
  • What are the 7MM historical and forecasted market of Acute Respiratory Distress Syndrome (ARDS)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome (ARDS).
  • To understand the future market competition in the ARDS market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) market.
  • To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market.

List of Companies:

  • Faron Pharmaceuticals
  • PhaseBio Pharmaceuticals
  • Sage Therapeutics
  • Chimerix
  • Direct Biologics
  • Kiniksa Pharmaceuticals
  • Pluristem Therapeutics
  • Alexion Pharmaceuticals
  • Biomarck Pharmaceuticals
  • Athersys
  • Veru
  • Apeptico Forschung und Entwicklung GmbH
  • Alexion Pharmaceuticals
  • Humanigen, Inc.
  • Roche Pharma AG
  • Alexion
  • Mylan Laboratories
  • Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
  • Laboratoire francais de Fractionnement et de Biotechnologies
  • Ache Laboratorios Farmaceuticos
  • Implicit Bioscience
  • Alexion
  • NeuroRx/Relief Therapeutics
  • CytoDyn
  • Kiniksa
  • Biohaven Pharmaceutical Holding Co. Ltd.
  • Kinevant Sciences GmbH/Roivant Sciences
  • Iltoo Pharma
  • Eli Lilly and Company
  • Merck/Eli Lilly
  • Apeiron Biologics
  • Roche AG
  • aTyr Pharma
  • Algernon Pharmaceuticals
  • Histocell, S.L.
  • Cellenkos Inc
  • Celularity Inc.; Sorrento Therapeutics Inc.; Lung Biotechnology PBC, a subsidiary of United Therapeutics Corp.
  • Hospital to Academy of Military Medical Sciences/Ivy Institute of Stem Cells Co. Ltd
  • Lattice Biologics Ltd.
  • Meridigen Biotech
  • Theravance Biopharma,
  • Mesoblast Limited
  • Aqualung Therapeutics Corp.
  • Diffusion Pharmaceuticals Inc.; University of Virginia
  • Lamellar Biomedical Ltd.
  • Leading Biosciences Inc.
  • Mannkind Corp.; Immix Biopharma Inc.
  • Medicinova Inc.
  • Bioxytran Inc.
  • Mallinckrodt plc
  • GEn1E Lifesciences
  • ZyVersa Therapeutics
  • Quark Pharmaceuticals
  • Navigen pharmaceuticals
  • XORTX Therapeutics
  • Tiziana
  • Bioaegis Therapeutics Inc.
  • Caladrius Biosciences Inc.
  • Cyclacel Pharmaceuticals
  • Mallinckrodt /Novoteris LLC
  • Noveome Biotherapeutics
  • Windtree Therapeutics
  • Ampio Pharmaceuticals Inc.
  • Cerecor Inc.
  • Predictive Biotech, of Salt Lake City, a subsidiary of Predictive Technology Group
  • Pharmazz
  • Noxopharm Co.
  • GlaxoSmithKline

Table of Contents

1 Key Insights

2 Executive Summary

3 Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance

  • 3.1 Total Market Share (%) Distribution of ARDS in 2017
  • 3.2 Total Market Share (%) Distribution of ARDS in 2030

4 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

  • 4.1 Introduction
    • 4.1.1 Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
    • 4.1.2 Development of Berlin Definition of ARDS
    • 4.1.3 Problems with the AECC definition and subsequent Berlin definition of acute respiratory distress syndrome (ARDS)
  • 4.2 Causes and Risk Factors
    • 4.2.1 Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
  • 4.3 Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)
    • 4.3.1 Inflammatory Processes in ARDS
    • 4.3.2 The initial event of injury
    • 4.3.3 Endothelial Damage
    • 4.3.4 Specific Mediators of Inflammation and Lung Damage in ARDS
    • 4.3.5 Altered Pulmonary Physiology in ARDS
    • 4.3.6 Genetics
  • 4.4 Stages of Acute Respiratory Distress Syndrome (ARDS)
  • 4.5 Ventilator-Induced Lung Injury (VILI)
  • 4.6 Major Determinants of VILI
    • 4.6.1 Ventilator determinants of VILI
    • 4.6.2 Patient determinants of VILI
  • 4.7 Diagnosis of Acute Respiratory Distress Syndrome (ARDS)
    • 4.7.1 Imaging techniques in ARDS
    • 4.7.2 Imaging findings in ARDS
    • 4.7.3 Differential Diagnosis

5 Case Reports

  • 5.1 Coronavirus Disease 2019 (COVID-19) Complicated by Acute Respiratory Distress Syndrome: An Internist's Perspective
  • 5.2 A fulminant case of Acute Respiratory Distress Syndrome associated with mycoplasma pneumonia treated with nasal high-flow oxygen therapy
  • 5.3 A case report of severe hypothermia complicated by acute respiratory distress syndrome

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Methodology

7 7MM Epidemiology Analysis

  • 7.1 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
  • 7.2 Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM

8 United States Epidemiology

  • 8.1 Assumptions and Rationale
  • 8.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States
  • 8.3 Severity-specific Incident Population of ARDS in the United States
  • 8.4 Incident Population of ARDS by Risk Factors in the United States

9 EU5 Epidemiology

  • 9.1 Germany Epidemiology
    • 9.1.1 Assumptions and Rationale
    • 9.1.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Germany
    • 9.1.3 Severity-specific Incidence of ARDS in Germany
    • 9.1.4 Incident Population of ARDS by Risk Factors in Germany
  • 9.2 France Epidemiology
    • 9.2.1 Assumptions and Rationale
    • 9.2.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), in France
    • 9.2.3 Severity-specific Incidence of ARDS in France
    • 9.2.4 Incident Population of ARDS by Risk Factors in France
  • 9.3 Italy Epidemiology
    • 9.3.1 Assumptions and Rationale
    • 9.3.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Italy
    • 9.3.3 Severity-specific Incidence of ARDS in Italy
    • 9.3.4 Incident Population of ARDS by Risk Factors in Italy
  • 9.4 Spain Epidemiology
    • 9.4.1 Assumptions and Rationale
    • 9.4.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Spain
    • 9.4.3 Severity-specific Incidence of ARDS in Spain
    • 9.4.4 Incident Population of ARDS by Risk Factors in Spain
  • 9.5 United Kingdom Epidemiology
    • 9.5.1 Assumptions and Rationale
    • 9.5.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United Kingdom
    • 9.5.3 Severity-specific Incidence of ARDS in the United Kingdom
    • 9.5.4 Incident Population of ARDS by Risk Factors in the United Kingdom

10 Japan Epidemiology

  • 10.1 Assumptions and Rationale
  • 10.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), ARDS in Japan
  • 10.3 Severity-specific Incidence of ARDS in Japan
  • 10.4 Incident Population of ARDS by Risk Factors in Japan

11 Treatment Algorithm, Current Treatment, and Medical Practices

  • 11.1 Treatment and Support for Acute Respiratory Distress Syndrome (ARDS)
  • 11.2 Treatment of ALI/ARDS associated with COVID-19

12 Proposed Guidelines for ARDS

  • 12.1 An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome
  • 12.2 The Clinical Practice Guideline by the Japanese Society of Respiratory Care Medicine and the Japanese Society of Intensive Care Medicine for the management of ARDS in Japan
  • 12.3 Infectious Diseases Society of America (IDSA) Guidelines on the Treatment and Management of Patients with COVID-19
  • 12.4 WHO guidance for the treatment ARDS associated with COVID-19

13 Unmet Needs

14 Off-Label Therapies for ARDS

  • 14.1 Neuromuscular Blocking Agents (NMBAs)
    • 14.1.1 Description
    • 14.1.2 Mechanism of Action
    • 14.1.3 Advantages and Disadvantages
    • 14.1.4 Clinical Development
  • 14.2 Inhaled Vasodilators
    • 14.2.1 Description
    • 14.2.2 Inhaled Pulmonary Vasodilators
    • 14.2.3 Advantages and Disadvantages
    • 14.2.4 Clinical Development
  • 14.3 Corticosteroids
    • 14.3.1 Description
    • 14.3.2 Mechanism of Action
    • 14.3.3 Advantages and Disadvantages
    • 14.3.4 Clinical Development

15 Emerging Therapies

  • 15.1 Key Cross Competition
    • 15.1.1 List of Products in development for ARDS/ALI
  • 15.2 Traumakine: Faron Pharmaceuticals
    • 15.2.1 Product Description
    • 15.2.2 Other Developmental Activities
    • 15.2.3 Clinical Development
    • 15.2.4 Clinical Trials Information
    • 15.2.5 Safety and Efficacy
    • 15.2.6 Product Profile
  • 15.3 Bio-11006: BioMarck Pharmaceuticals
    • 15.3.1 Product Description
    • 15.3.2 Other Developmental Activities
    • 15.3.3 Clinical Development
    • 15.3.4 Clinical Trials Information
    • 15.3.5 Safety and Efficacy
    • 15.3.6 Product Profile
  • 15.4 MultiStem: Athersys
    • 15.4.1 Product Description
    • 15.4.2 Other Developmental Activities
    • 15.4.3 Clinical Development
    • 15.4.4 Clinical Trials Information
    • 15.4.5 Safety and Efficacy
    • 15.4.6 Product Profile
  • 15.5 Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
    • 15.5.1 Product Description
    • 15.5.2 Other Developmental Activities
    • 15.5.3 Clinical Development
    • 15.5.4 Clinical Trials Information
    • 15.5.5 Safety and Efficacy
    • 15.5.6 Product Profile
  • 15.6 Ultomiris (ravulizumab-cwvz): Alexion Pharma
    • 15.6.1 Product Description
    • 15.6.2 Other Developmental Activities
    • 15.6.3 Clinical Development
    • 15.6.4 Product Profile
  • 15.7 Soliris (eculizumab): Alexion Pharma
    • 15.7.1 Product Description
    • 15.7.2 Other Developmental Activities
    • 15.7.3 Clinical Development
    • 15.7.4 Product Profile

16 Unknown Status

  • 16.1 Ulinastatin: Techpool Bio-Pharma
    • 16.1.1 Product Description
    • 16.1.2 Other Developmental Activities
    • 16.1.3 Clinical Development
    • 16.1.4 Clinical Trials Information
    • 16.1.5 Product Profile

17 COVID-19 associated with ARDS: Emerging Drugs

  • 17.1 L-citrulline: Asklepion Pharmaceuticals
    • 17.1.1 Product Description
    • 17.1.2 Other Developmental Activities
    • 17.1.3 Clinical Development
    • 17.1.4 Product Profile
  • 17.2 Cholecalciferol: Mylan Laboratories
    • 17.2.1 Product Description
    • 17.2.2 Clinical Development
    • 17.2.3 Product Profile
  • 17.3 Ruxolitinib: Incyte Corporation/Novartis
    • 17.3.1 Product Description
    • 17.3.2 Other Developmental Activities
    • 17.3.3 Clinical Development
    • 17.3.4 Safety and Efficacy
    • 17.3.5 Product Profile
  • 17.4 BDB-001: Staidson (Beijing) Biopharmaceuticals
    • 17.4.1 Product Description
    • 17.4.2 Other Developmental Activities
    • 17.4.3 Clinical Development
    • 17.4.4 Product Profile
  • 17.5 RLF-100 (aviptadil): NeuroRx/Relief Therapeutics
    • 17.5.1 Product Description
    • 17.5.2 Other Developmental Activities
    • 17.5.3 Clinical Development
    • 17.5.4 Safety and Efficacy
    • 17.5.5 Product Profile
  • 17.6 Zavegepant/Vazegepant: Biohaven Pharmaceutical
    • 17.6.1 Product Description
    • 17.6.2 Other Developmental Activities
    • 17.6.3 Clinical Development
    • 17.6.4 Product Profile
  • 17.7 Metablok (LSALT peptide): Arch Biopartners
    • 17.7.1 Product Description
    • 17.7.2 Other Developmental Activities
    • 17.7.3 Clinical Development
    • 17.7.4 Safety and Efficacy
    • 17.7.5 Product Profile
  • 17.8 Lenzilumab: Humanigen
    • 17.8.1 Product Description
    • 17.8.2 Other Developmental Activities
    • 17.8.3 Clinical Development
    • 17.8.4 Safety and Efficacy
    • 17.8.5 Product Profile
  • 17.9 Actemra/RoActemra (Tocilizumab): Roche Pharma AG
    • 17.9.1 Product Description
    • 17.9.2 Other Developmental Activities
    • 17.9.3 Clinical Development
    • 17.9.4 Safety and Efficacy
    • 17.9.5 Product Profile
  • 17.10 DSTAT (Dociparastat sodium): Chimerix
    • 17.10.1 Product Description
    • 17.10.2 Other Developmental Activities
    • 17.10.3 Clinical Development
    • 17.10.4 Product Profile
  • 17.11 Pemziviptadil (PB1046): PhaseBio Pharmaceuticals
    • 17.11.1 Product Description
    • 17.11.2 Other Developmental Activities
    • 17.11.3 Clinical Development
    • 17.11.4 Safety and Efficacy
    • 17.11.5 Product Profile
  • 17.12 ExoFlo (DB-001): Direct Biologics
    • 17.12.1 Product Description
    • 17.12.2 Other Developmental Activities
    • 17.12.3 Clinical Development
    • 17.12.4 Safety and Efficacy
    • 17.12.5 Product Profile
  • 17.13 Veru-111: Veru
    • 17.13.1 Product Description
    • 17.13.2 Clinical Development
    • 17.13.3 Safety and Efficacy
    • 17.13.4 Product Profile
  • 17.14 Tradipitant: Vanda Pharmaceuticals
    • 17.14.1 Product Description
    • 17.14.2 Other Developmental Activities
    • 17.14.3 Clinical Development
    • 17.14.4 Safety and Efficacy
    • 17.14.5 Product Profile
  • 17.15 Brexanolone: Sage Therapeutics
    • 17.15.1 Product Description
    • 17.15.2 Other Developmental Activities
    • 17.15.3 Clinical Development
    • 17.15.4 Product Profile
  • 17.16 Mavrilimumab: Kiniksa Pharmaceuticals
    • 17.16.1 Product Description
    • 17.16.2 Other Developmental Activities
    • 17.16.3 Clinical Development
    • 17.16.4 Safety and Efficacy
    • 17.16.5 Product Profile
  • 17.17 Human immunoglobulin: Laboratoire francais de Fractionnement et de Biotechnologies (LFB)
    • 17.17.1 Product Description
    • 17.17.2 Clinical Development
    • 17.17.3 Product Profile
  • 17.18 Remestemcel-L: Mesoblast Limited
    • 17.18.1 Product Description
    • 17.18.2 Other Developmental Activities
    • 17.18.3 Clinical Development
    • 17.18.4 Product Profile
  • 17.19 PLX-PAD: Pluristem Therapeutics
    • 17.19.1 Product Description
    • 17.19.2 Other Developmental Activities
    • 17.19.3 Clinical Development
    • 17.19.4 Safety and Efficacy
    • 17.19.5 Product Profile
  • 17.20 CERC-002: Cerecor
    • 17.20.1 Product Description
    • 17.20.2 Other Developmental Activities
    • 17.20.3 Clinical Development
    • 17.20.4 Safety and Efficacy
    • 17.20.5 Product Profile
  • 17.21 TD-0903: Theravance Biopharma
    • 17.21.1 Product Description
    • 17.21.2 Clinical Development
    • 17.21.3 Product Profile
  • 17.22 ILT101: ILTOO Pharma
    • 17.22.1 Product Description
    • 17.22.2 Clinical Development
    • 17.22.3 Product Profile

18 Discontinued Products

  • 18.1 APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline
    • 18.1.1 Product Description
    • 18.1.2 Other Developmental Activities
    • 18.1.3 Clinical Development
    • 18.1.4 Safety and Efficacy
    • 18.1.5 Product Profile
  • 18.2 GSK2862277: GlaxoSmithKline
    • 18.2.1 Product Description
    • 18.2.2 Other Developmental Activities
    • 18.2.3 Clinical Development
    • 18.2.4 Safety and Efficacy
    • 18.2.5 Product Profile
  • 18.3 Remodulin (Treprostinil Inhalation Solution): United Therapeutics
    • 18.3.1 Product Description
    • 18.3.2 Other Developmental Activities
    • 18.3.3 Clinical Development
    • 18.3.4 Clinical Trials Information
    • 18.3.5 Product Profile

19 Acute Respiratory Distress Syndrome (ARDS): 7MM Market Analysis

  • 19.1 Key Findings
  • 19.2 Current Market Size: Forecast Assumptions
  • 19.3 Market Size of ARDS in the 7MM countries
  • 19.4 Market Size of ARDS by therapies in the 7MM

20 Attribute Analysis

21 Key Emerging Therapies: Market Forecast Assumptions

22 United States: Market Outlook

  • 22.1 United States Market Size
    • 22.1.1 Total Market size of ARDS
    • 22.1.2 Market Size of ARDS by Therapies in the US

23 EU-5 Countries: Market Outlook

  • 23.1 Germany Market Size
    • 23.1.1 Total Market Size of ARDS
    • 23.1.2 Market Size of ARDS by Therapies in Germany
  • 23.2 France Market Size
    • 23.2.1 Total Market Size of ARDS
    • 23.2.2 Market Size of ARDS by Therapies in France
  • 23.3 Italy Market Size
    • 23.3.1 Total Market Size of ARDS
    • 23.3.2 Market Size of ARDS by Therapies in Italy
  • 23.4 Spain Market Size
    • 23.4.1 Total Market Size of ARDS
    • 23.4.2 Market Size of ARDS by Therapies in Spain
  • 23.5 United Kingdom Market Size
    • 23.5.1 Total Market Size of ARDS
    • 23.5.2 Market Size of ARDS by Therapies in the UK

24 Japan Market Outlook

  • 24.1 Japan Market Size
    • 24.1.1 Total Market Size of ARDS
    • 24.1.2 Market Size of ARDS by Therapies in Japan

25 Access and Reimbursement

26 Market Drivers

27 Market Barriers

28 SWOT Analysis

29 Appendix

  • 29.1 Report Methodology

30 DelveInsight Capabilities

31 Disclaimer

32 About DelveInsight

List of Tables

  • Table 1 Summary of Acute Respiratory Distress Syndrome (ARDS) Market, Epidemiology and Key Events (2017-2030)
  • Table 2 Definition of Acute Respiratory Distress Syndrome (ARDS)
  • Table 3 American European Consensus Conference Criteria for Acute Lung Injury (ALI) and the Acute Respiratory Distress Syndrome (ARDS)
  • Table 4 Berlin Definition of Mild, Moderate, and Severe Acute Respiratory Distress Syndrome (ARDS)
  • Table 5 Factors That Distinguish ARDS, CHF, and Pneumonia
  • Table 6 Total Incident Population of ARDS in the 7MM (2017-2030)
  • Table 7 Severity-specific Incident Population of ARDS in the 7MM (2017-2030)
  • Table 8 Total Incident Population of ARDS in the US (2017-2030)
  • Table 9 Severity-specific Incident Population of ARDS in the US (2017-2030)
  • Table 10 Incidence of ARDS by Risk Factors in the US (2017-2030)
  • Table 11 Total Incident Population of ARDS in Germany (2017-2030)
  • Table 12 Severity-specific Incident Population of ARDS in Germany (2017-2030)
  • Table 13 Incidence of ARDS by Risk Factors in Germany (2017-2030)
  • Table 14 Total Incident Population of ARDS in France (2017-2030)
  • Table 15 Severity-specific Incident Population of ARDS in France (2017-2030)
  • Table 16 Incidence of ARDS by Risk Factors in France (2017-2030)
  • Table 17 Total Incident Population of ARDS in Italy (2017-2030)
  • Table 18 Severity-specific Incident Population of ARDS in Italy (2017-2030)
  • Table 19 Incidence of ARDS by Risk Factors in Italy (2017-2030)
  • Table 20 Total Incident Population of ARDS in Spain (2017-2030)
  • Table 21 Severity-specific Incident Population of ARDS in Spain (2017-2030)
  • Table 22 Incidence of ARDS by Risk Factors in Spain (2017-2030)
  • Table 23 Total Incident Population of ARDS in the UK (2017-2030)
  • Table 24 Severity-specific Incident Population of ARDS in the UK (2017-2030)
  • Table 25 Incidence of ARDS by Risk Factors in the UK (2017-2030)
  • Table 26 Total Incident Population of ARDS in Japan (2017-2030)
  • Table 27 Severity-specific Incident Population of ARDS in Japan(2017-2030)
  • Table 28 Incidence of ARDS by Risk Factors in Japan (2017-2030)
  • Table 29 Management of Acute Respiratory Distress Syndrome (ARDS)
  • Table 30 Spontaneous Breathing Trial: Eligibility and Weaning Parameters
  • Table 31 Therapeutic options for severe acute respiratory distress syndrome related to coronavirus disease 2019
  • Table 32 Recommendations for Specific Treatment Questions for the Management of ARDS
  • Table 33 The Clinical Practice Guideline for The Management of ARDS in Japan
  • Table 34 Recommendations by the Infectious Diseases Society of America
  • Table 35 Randomized trials of Methylprednisolone for ARDS prevention
  • Table 36 Comparison of Emerging Drugs
  • Table 37 Key Cross
  • Table 38 Traumakine, Clinical Trial Description, 2020
  • Table 39 Bio-11006, Clinical Trial Description, 2020
  • Table 40 MultiStem, Clinical Trial Description, 2020
  • Table 41 Solnatide (AP301), Clinical Trial Description, 2020
  • Table 42 Soliris, Clinical Trial Description, 2020
  • Table 43 Ulinastatin, Clinical Trial Description, 2020
  • Table 44 L-citrulline, Clinical Trial Description, 2020
  • Table 45 Cholecalciferol, Clinical Trial Description, 2020
  • Table 46 Ruxolitinib, Clinical Trial Description, 2020
  • Table 47 BDB-001, Clinical Trial Description, 2020
  • Table 48 RLF-100 (aviptadil), Clinical Trial Description, 2020
  • Table 49 Vazegepant, Clinical Trial Description, 2020
  • Table 50 LSALT peptide, Clinical Trial Description, 2020
  • Table 51 Lenzilumab, Clinical Trial Description, 2020
  • Table 52 Tocilizumab, Clinical Trial Description, 2020
  • Table 53 DSTAT, Clinical Trial Description, 2020
  • Table 54 Pemziviptadil, Clinical Trial Description, 2020
  • Table 55 ExoFlo (DB-001), Clinical Trial Description, 2020
  • Table 56 VERU-111, Clinical Trial Description, 2020
  • Table 57 Tradipitant, Clinical Trial Description, 2020
  • Table 58 Brexanolone, Clinical Trial Description, 2020
  • Table 59 Mavrilimumab, Clinical Trial Description, 2020
  • Table 60 Human Immunoglobulin, Clinical Trial Description, 2020
  • Table 61 Remestemcel-L, Clinical Trial Description, 2020
  • Table 62 PLX-PAD Clinical Trial Description, 2020
  • Table 63 CERC-002, Clinical Trial Description, 2020
  • Table 64 TD-0903, Clinical Trial Description, 2020
  • Table 65 ILT-101, Clinical Trial Description, 2020
  • Table 66 APN01 (GSK2586881), Clinical Trial Description, 2020
  • Table 67 GSK2862277, Clinical Trial Description, 2020
  • Table 68 Remodulin (Treprostinil Inhalation Solution), Clinical Trial Description, 2020
  • Table 69 7 Major Market Size of ARDS in the 7MM, USD Million (2017-2030)
  • Table 70 Market size of ARDS by therapies in the 7MM, in USD Million (2017-2030)
  • Table 71 Key Market Forecast Assumptions for Solnatide
  • Table 72 Key Market Forecast Assumptions for Multistem
  • Table 73 Key Market Forecast Assumptions for BIO-11006
  • Table 74 Key Market Forecast Assumptions for Traumakine
  • Table 75 Key Market Forecast Assumptions for Lenzilumab
  • Table 76 Key Market Forecast Assumptions for Actemra/RoActemra (Tocilizumab)
  • Table 77 Key Market Forecast Assumptions for RLF-100 (aviptadil)
  • Table 78 Key Market Forecast Assumptions for Ruxolitinib
  • Table 79 Key Market Forecast Assumptions for Tradipitant
  • Table 80 Key Market Forecast Assumptions for Remestemcel-L
  • Table 81 United States Market Size of ARDS, USD Million (2017-2030)
  • Table 82 Market size of ARDS by therapies in the US, in USD Million (2017-2030)
  • Table 83 Germany Market Size of ARDS, in USD Million (2017-2030)
  • Table 84 Market size of ARDS by therapies in Germany, in USD Million (2017-2030)
  • Table 85 France Market Size of ARDS, in USD Million (2017-2030)
  • Table 86 Market size of ARDS by therapies in France, in USD Million (2017-2030)
  • Table 87 Italy Market Size of ARDS, in USD Million (2017-2030)
  • Table 88 Market size of ARDS by therapies in Italy, in USD Million (2017-2030)
  • Table 89 Spain Market Size of ARDS, in USD Million (2017-2030)
  • Table 90 Market size of ARDS by therapies in Spain, in USD Million (2017-2030)
  • Table 91 United Kingdom Market Size of ARDS, in USD Million (2017-2030)
  • Table 92 Market size of ARDS by therapies in the UK, in USD Million (2017-2030)
  • Table 93 Japan Market Size of ARDS, in USD Million (2017-2030)
  • Table 94 Market size of ARDS by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1 Risk factors of Acute Respiratory Distress Syndrome (ARDS)
  • Figure 2 A simplified model of the pathogenesis of ARDS
  • Figure 3 Effects of Mast Cell Activation
  • Figure 4 Total Incident Population of ARDS in the 7MM (2017-2030)
  • Figure 5 Severity specific Incident Population of ARDS in the 7MM (2017-2030)
  • Figure 6 Total Incident Population of ARDS in the US (2017-2030)
  • Figure 7 Severity-specific Incidence of ARDS in the US (2017-2030)
  • Figure 8 Incidence of ARDS by Risk Factors in the US (2017-2030)
  • Figure 9 Total Incident Population of ARDS in Germany (2017-2030)
  • Figure 10 Severity-specific Incidence of ARDS in Germany (2017-2030)
  • Figure 11 Incident Population of ARDS by Risk Factors in Germany (2017-2030)
  • Figure 12 Total Incident Population of ARDS in France (2017-2030)
  • Figure 13 Severity-specific Incidence of ARDS in France (2017-2030)
  • Figure 14 Incident Population of ARDS by Risk Factors in France (2017-2030)
  • Figure 15 Total Incident Population of ARDS in Italy (2017-2030)
  • Figure 16 Severity-specific Incidence of ARDS in Italy (2017-2030)
  • Figure 17 Incidence of ARDS by Risk Factors in Italy (2017-2030)
  • Figure 18 Total Incident Population of ARDS in Spain (2017-2030)
  • Figure 19 Severity-specific Incidence of ARDS in Spain (2017-2030)
  • Figure 20 Incident Population of ARDS by Risk Factors in Spain (2017-2030)
  • Figure 21 Total Incident Population of ARDS in the UK (2017-2030)
  • Figure 22 Severity-specific Incidence of ARDS in the UK (2017-2030)
  • Figure 23 Incident Population of ARDS by Risk Factors in the UK (2017-2030)
  • Figure 24 Total Incident Population of ARDS in Japan (2017-2030)
  • Figure 25 Severity-specific Incidence of ARDS in Japan (2017-2030)
  • Figure 26 Incident Population of ARDS by Risk Factors in Japan (2017-2030)
  • Figure 27 Treatment Algorithm for ARDS
  • Figure 28 Unmet Needs of ARDS
  • Figure 29 Market Size of ARDS in the 7MM in USD Million (2017-2030)
  • Figure 30 Market Size of ARDS by therapies in the 7MM in USD Million (2017-2030)
  • Figure 31 Market Size of ARDS in the US, USD Millions (2017-2030)
  • Figure 32 Market Size of ARDS by therapies in the United States in USD Million (2017-2030)
  • Figure 33 Market Size of ARDS in Germany, USD Millions (2017-2030)
  • Figure 34 Market Size of ARDS by therapies in Germany in USD Million (2017-2030)
  • Figure 35 Market Size of ARDS in France, USD Millions (2017-2030)
  • Figure 36 Market Size of ARDS by therapies in France in USD Million (2017-2030)
  • Figure 37 Market Size of ARDS in Italy, USD Millions (2017-2030)
  • Figure 38 Market Size of ARDS by therapies in Italy in USD Million (2017-2030)
  • Figure 39 Market Size of ARDS in Spain, USD Millions (2017-2030)
  • Figure 40 Market Size of ARDS by therapies in Spain in USD Million (2017-2030)
  • Figure 41 Market Size of ARDS in the UK, USD Millions (2017-2030)
  • Figure 42 Market Size of ARDS by therapies in the UK in USD Million (2017-2030)
  • Figure 43 Market Size of ARDS in Japan, USD Millions (2017-2030)
  • Figure 44 Market Size of ARDS by therapies in Japan in USD Million (2017-2030)
  • Figure 45 Market Drivers
  • Figure 46 Market Barriers
  • Figure 47 Acute respiratory distress syndrome (ARDS) SWOT Analysis